Journal of Vaccines & Vaccination

A novel approach to inhibit human immune deficiency virus (HIV-1) infection by actively neutralizing the antibodies of reverse transcriptase system

6^th Euro Global Summit and Expo on Vaccines & Vaccination

August 17-19, 2015 Birmingham, UK

Sherif Salah

Posters-Accepted Abstracts: J Vaccines Vaccin

Abstract:

This work was applied to study the effect of a novel enzymes combination comprising reverse transcriptase and DNA
polymerase (VK 25 RD formula) as immunogens to stimulate the formation of neutralizing non-specific mAbs to AMV–
RT enzyme that can block the activity of HIV-RT enzyme system by cross reaction for treatment of HIV. Pilot study was applied
on ten patients, their immunological data revealed a viral load of more than 1,000 copies/ml by human immune deficiency
virus-ribonucleic acid-polymerase chain reaction (HIV-RNA-PCR), positive antibody to HIV-1 and CD4+ T-cell values less
than 250 cells/μl. Five patients take this medication in the form of subcutaneous injection of 0.1 cc twice daily for 24 weeks (test
group) and the other five contributed to the study by giving only blood samples during 24 weeks (control group). All of the
patients showed the same clinical symptoms of HIV/AIDS and wrote consent of acceptance to take this combination therapy.
Blood samples were collected from all ten patients at 6, 12, 18 and 24 weeks. At the end of therapy the test group viral loads
had reached under the detectable limits (less than 16 copies/ml), significant increases of their CD4 cells count over 500 cells/
μl and the most important finding of great immunological value is that HIV antibodies by Enzyme-Linked Immunosorbent
Assay (ELISA) testing were negatives. According to these findings, this therapeutic modality was promising for treating HIV-1
disease and human immunodeficiency syndrome.